Welcome to our dedicated page for Teleflex news (Ticker: TFX), a resource for investors and traders seeking the latest updates and insights on Teleflex stock.
Teleflex Inc (NYSE: TFX) is a global medical technology leader developing devices that enhance patient care across surgical, interventional, and critical care settings. This news hub provides investors and healthcare professionals with timely updates on TFX's clinical advancements, regulatory milestones, and strategic initiatives.
Access authoritative reporting on product innovations like the UroLift system, vascular access solutions, and anesthesia devices that demonstrate Teleflex's commitment to evidence-based medicine. Our curated news collection covers essential developments including quarterly earnings, FDA clearances, partnership announcements, and clinical trial outcomes.
Key updates focus on Teleflex's core therapeutic areas: minimally invasive surgical tools, critical care devices, and urology solutions. Stay informed about technologies improving procedural safety and healthcare economics through verified press releases and objective analysis.
Bookmark this page for consolidated access to Teleflex's latest progress in medical device innovation, financial performance data, and market expansion efforts. Regularly updated to serve as your primary resource for understanding TFX's role in advancing global medical standards.
Teleflex Incorporated (NYSE: TFX) has successfully completed patient enrollment ahead of schedule in its clinical study evaluating specialty catheters and coronary guidewires for Chronic Total Occlusion (CTO) percutaneous coronary interventions. The study enrolled 150 patients across 13 US sites, concluding three months early. CTOs affect nearly 20% of patients undergoing coronary angiography, often leading to severe ischemia and cardiac dysfunction. The study aims to assess device performance and safety, with expectations for results to inform clinical practices in CTO procedures.
Teleflex Incorporated (NYSE: TFX) announced that Chairman, President, and CEO Liam Kelly will speak at the Raymond James 42nd Annual Institutional Investors Conference on March 2, 2021, at 12:30 p.m. ET. A live audio webcast and accompanying slides will be accessible on the investor section of Teleflex's website. Teleflex is dedicated to enhancing healthcare through innovative medical technologies across various specialties.
Teleflex Incorporated (NYSE: TFX) will announce its Q4 2020 and full-year financial results on February 25, 2021, before market open. A live conference call will occur at 8:00 a.m. ET on the same day, accessible via audio webcast on the company’s website. An audio replay will be available from 11:00 a.m. ET on February 25, 2021, until 11:00 a.m. ET on March 2, 2021. Teleflex is a leading provider of medical technologies aimed at enhancing health and quality of life.
Teleflex Incorporated (NYSE: TFX) announced new data published in European Urology Focus, indicating that the Prostatic Urethral Lift (PUL) procedure using the UroLift® System significantly preserves and improves sexual function compared to medical treatment for benign prostatic hyperplasia (BPH). The study showed a 17% and 21% increase in erectile function at 1 and 2 years, respectively, and substantial improvements in ejaculatory function over four years. Meanwhile, medication treatments generally led to declines in sexual function. These findings underscore UroLift's benefits for BPH patients.
Teleflex expands its ErgoPack® Complete system by introducing new Arrow® Multi-Lumen Access Catheter (MAC) and Percutaneous Sheath Introducer (PSI) systems, enhancing vascular access solutions. Building on the October 2020 launch of the ErgoPack® Complete CVC System, these innovations incorporate clinician-inspired features such as a GlideWheel™ Advancer and kink-resistant guidewire. These enhancements aim to reduce catheter-related complications, adhering to CDC and SHEA guidelines while offering broad-spectrum antimicrobial protection against pathogens.
Teleflex, a global medical technology provider, announced that its Chairman and CEO, Liam Kelly, will present at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 8:20 a.m. ET. An audio webcast and slide presentation will be accessible on the investor section of the Teleflex website. Teleflex focuses on innovative healthcare solutions in various fields, including vascular access, anesthesia, and emergency medicine, aiming to improve the lives of patients and healthcare providers.
DW Healthcare Partners has successfully closed the sale of Z-Medica to Teleflex (NYSE: TFX). Z-Medica specializes in manufacturing hemostatic products crucial for controlling bleeding. DWHP initially invested in Z-Medica in 2012, significantly growing the business through product development and channel diversification. This sale follows Z-Medica's successful evolution into a major player in the hemostatic market, largely attributed to strategic partnerships and innovative products like QuickClot Control+®.
Teleflex (NYSE:TFX) has successfully completed the acquisition of Z-Medica for $500 million, with a potential additional $25 million based on performance milestones. This strategic buy aims to enhance Teleflex's medical technology portfolio, specifically in hemorrhage control products, which are critical for healthcare providers. The acquisition is not anticipated to have a significant impact on 2020 revenue but is expected to contribute between $60 million and $70 million in revenue and $0.07 to $0.15 in adjusted EPS for 2021, with potential for high-single digit growth thereafter.
Teleflex Incorporated has been recognized as one of the best places to work in medical sales for the fourth consecutive year, according to MedReps.com’s 2021 survey. Teleflex ranked first in the Large Category for Best Medical Device Companies and second overall among medical sales companies. The survey, which included over 2,000 respondents, highlights the company's positive corporate culture and commitment to employee welfare during the COVID-19 pandemic. Teleflex emphasizes innovation and values that prioritize both patient care and employee experience.
